New Atlas3h
Weight-loss pill passes important safety test in clinical trial
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
Is Viking Therapeutics a Buy on the Dip?
Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...
A stronger Ozempic, a Boeing supplier in trouble, and a simpler Starbucks: Business news roundup
Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
Worried about the future? History proves it’s hard to predict
Fifty years ago, 20 of the world's brightest people tried to predict life in 2024. They got an awful lot wrong.
Ozempic’s maker wants the US government to ban cheaper versions of the high-priced $969 injection weight-loss drug – claims the formula is ‘too complex’ to cop…
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
Counterfeit weight loss drugs sold online, feeding demand for cheaper options
A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of seemingly reputable online pharmacies in search of weight loss drugs ... to ...
Becker's Hospital Review2d
3 Ozempic updates: Competition, warnings and potential uses
A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...